HealthPharma & Biotech
Dechra Pharmaceutical

Dechra Pharmaceuticals revenue growth slows slightly in second half

In the 12 months to end-June, the FTSE 250-listed firm's revenues were up by around 17% on the previous year, which was slower than the 19.1% growth seen in the first six months

Dechra's North American Pharmaceuticals business faced more competition in the second half

Veterinary drug maker Dechra Pharmaceuticals PLC (LON:DPH) said a mix of organic growth and acquisitions led to revenues growing 18% in the past 12 months.

In a brief trading update on Tuesday, the FTSE 250-listed firm said group revenue at constant currency rates in the year to end-June were by up around 17% on the £407.1mln reported in the previous year, albeit slower than the 19.1% growth seen in the first six months of the year.

READ: JP Morgan kicks off Dechra Pharmaceutical coverage with bullish ‘overweight’ note

The companys said its strongest growth came from its European Pharmaceuticals business, up roughly 18%, helped by the acquisition of Netherlands-based Le Vet halfway through the prior year and the further purchases of antipodes-based Caledonian and Brazil’s Venco in the latest year.

Excluding third party contract manufacturing, treating previous year’s acquisitions on a like-for-like basis, and excluding the latest purchases, Dechra said its full-year revenues increased by around 7%.

In North America Pharmaceuticals revenue growth was around 15%, driven by the companion animal portfolio, which was a strong outperformance of the market, the company noted, even though it was down on the 19.3% seen in the first half of the financial year when a key competitor product was absent from the market. 

“We are pleased to have delivered another year of strong revenue growth,” said Dechra chief executive Ian Page. “This has been driven from our core portfolio, good market penetration and realisation of significant Le Vet revenue synergies.”

He added that the newly acquired Caledonian and Venco businesses have “performed well”.

Shares in Dechra, which will publish its full results in early September, were up 1% to 2,786p in early trading on Tuesday. 

Quick facts: Dechra Pharmaceutical

Price: 2544 GBX

Market: LSE
Market Cap: £2.62 billion


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...



Shield Therapeutics to present data showing Feraccru offers 'real oral...

Shield Therapeutics PLC's (LON:STX) Dr Mark Sampson speaks to Proactive London's Andrew Scott ahead of them presenting positive data from the Phase 3b, open-label randomised controlled trial of Feraccru. He says the trial shows the drug, also known as Accrufer in the States, offers a real...

14 hours, 49 minutes ago


Result of AGM 2019

4 days, 9 hours ago

AGM Trading Update

4 days, 17 hours ago

Holding(s) in Company

3 weeks ago

Total Voting Rights

3 weeks, 2 days ago

2 min read